Description
Anti-CCR2 Antibody, Highly Galactosylated (BioBet-GA-097ZP) is a humanized IgG1, κ antibody against CCR2 which contains with a high level of galactosylation.
Antibody Indication
Atherosclerosis, Diabetic nephropathies, Malignant melanoma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CCR2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CCR2
Full Name
C-C Motif Chemokine Receptor 2
Background
CCR2 (C-C Motif Chemokine Receptor 2) is a Protein Coding gene.
Diseases associated with CCR2 include Idiopathic Anterior Uveitis and Cd3zeta Deficiency.
Among its related pathways are Cytokine Signaling in Immune system and Defensins.
Gene Ontology (GO) annotations related to this gene include G-protein coupled receptor activity and chemokine receptor activity.
An important paralog of this gene is CCR5.
Alternative Names
Chemokine (C-C Motif) Receptor 2; Monocyte Chemoattractant Protein 1 Receptor; CC-CKR-2; MCP-1-R; CMKBR2; CCR-2; Monocyte Chemotactic Protein 1 Receptor; MCP-1 Receptor; CD192 Antigen; C-C CKR-2; CCR2A; CCR2B; CD192; CKR2A; CKR2B;
Gene ID
729230
UniProt ID
P41597
Cellular Localization
Plasma membrane
Genecards
1603
Involvement in Disease
Its related pathways are Signaling by GPCR and Defensins.
Related Pathways
The key functional receptor of CCL2, but it can also bind to CCL7 and CCL12 (PubMed:8146186, PubMed:8048929, PubMed:23408426). It binds to CCL2 on monocytes and macrophages, and induces chemotaxis and migration (possibly) by activating the PI3K cascade, small G protein Rac, and plate platform protrusions. It also acts as a receptor for the defensin DEFB106A/DEFB106B (PubMed:23938203). Regulates the expression of T cell inflammatory factors and T cell differentiation, and promotes T cell differentiation into T-helper 17 cells (Th17) (through similarity) during inflammation. Promote the output of mature thymocytes, enhance the directional movement of thymocytes stimulated by sphingosine-1-phosphate and up-regulate S1P1R expression; regulate FOXO1 activity through the JAK-STAT pathway, resulting in increased S1P1R expression (through similarity). Plays an important role in mediating neuropathic pain caused by peripheral nerve injury (similar). The increase in nmda-mediated synaptic transmission in both dopamine D1 and D2 receptor neurons may be caused by MAPK/erk-dependent phosphorylation of GRIN2B/NMDAR2B (similarity). Mediates the aggregation of macrophages and monocytes to the injury site after brain injury (by similarity).
Field of research
1.N-glycosylated. 2.Sulfation increases the affinity for both monomeric and dimeric CCL2 with stronger binding to the monomeric form. Binding of sulfated CCR2 to CCL2 promotes conversion of CCL2 from dimer to monomer.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-GA-097ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CCR2. Plozalizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Atherosclerosis, Diabetic nephropathies, Malignant melanoma. It binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2.
Antibody Indication
Atherosclerosis, Diabetic nephropathies, Malignant melanoma
Atherosclerosis, Diabetic nephropathies, Malignant melanoma
